《恒瑞医药关于公司药品纳入国家医保目录的公告》 恒瑞医药近日发布公告称，其多个药品纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2025 年）》。其中包括注射用瑞康曲妥珠单抗、苹果酸法米替尼胶囊等首次纳入品种，注射用卡瑞利珠单 抗、氟唑帕利胶囊等新增适应症品种，以及马来酸吡咯替尼片、海曲泊帕乙醇胺片等续约品种。部分药 品新增适应症并调整至常规目录管理。上述药品2024年度合计销售额约86.60亿元，2025年1-3季度合计 销售额约75.54亿元。国家医保目录将于2026年1月1日起实施，具体支付标准以官方公布为准。 最新公告列表 截至2025年12月8日收盘，恒瑞医药（600276）报收于62.46元，较前一交易日上涨1.36%，最新总市值 为4145.6亿元。该股当日开盘62.6元，最高63.55元，最低61.92元，成交额达31.87亿元，换手率为 0.8%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Points - The company has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and improve operational performance [1] - The total estimated sales for the included drugs in 2024 is approximately 8.66 billion yuan, and for the first three quarters of 2025, it is about 7.55 billion yuan [1] Drug Inclusion in National Medical Insurance Catalog - The following drugs have been newly included: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Zhumab - Sulfate of Amatuximab Tablets - Injection of Phosphorola Pitant Palonosetron - Injection of Ruikasi Zhumab - Acetate of Abiraterone Tablets (II) - Lipid Injection of Irinotecan Hydrochloride (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following drugs have successfully added new indications: - Injection of Karelizumab - Fluorazepam Capsules - Injection of Fumaric Acid Tegafur [1] - The following drugs have been renewed and retained in the National Medical Insurance Catalog: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Methylsulfonylmethane Remazolam - Sulfate of Pevonedistat Injection [1] - The following drugs have new indications and have been adjusted to regular catalog management: - Mesylate of Apatinib Tablets - Lipid Injection of Bupivacaine [1] Impact on the Company - The inclusion of these drugs in the National Medical Insurance Catalog is expected to positively impact sales, although the exact effect on the company's operational performance is currently indeterminate [1] - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be announced by relevant government departments [1]

Corporate Announcements - China Pacific Insurance announced that Vice President Yu Ze is under investigation for serious violations of discipline and law, but this will not affect the company's management [2] - Guanglian Aviation reported that its controlling shareholder and chairman Wang Zengduo has had his detention lifted, allowing him to resume his duties, with normal operations continuing [3] - China Communications Construction Company clarified that it bears no repayment or guarantee obligations related to overdue financial products linked to its controlling shareholder, and its operations remain normal [4] - Annie Co. is planning a change in control, with stock trading resuming on December 8, 2025, after a share transfer agreement is signed [5] - Guoao Technology announced that its actual controller is planning a change in control, leading to a temporary suspension of its stock [6] - ST Tianrui terminated its planned change in control due to a lack of consensus, with stock resuming trading on December 8, 2025 [7] Industry Developments - Double Star New Materials noted that leading companies in the BOPET industry have reached a consensus on production cuts to balance supply and demand, although the sustainability of long-term price increases remains uncertain [8] - First Venture received a notice of administrative penalty for failing to diligently supervise a bond project, resulting in fines and warnings, but this will not significantly impact its operations [12] - China Chemical announced that its nylon new materials project has reached full production capacity, enhancing efficiency and market competitiveness [14] Pharmaceutical Sector Updates - Hengrui Medicine reported that nine of its drugs have been included in the national medical insurance directory, with a total expected sales of approximately 8.66 billion yuan for 2024 [15] - Junshi Biosciences announced that its products have received new indications and have been included in the national medical insurance directory, enhancing market accessibility [16] - Huadong Medicine's subsidiary has had its products included in the national medical insurance and commercial insurance innovation drug directories, aiding market promotion [17] - Aidi Pharmaceutical's two innovative HIV drugs have been renewed for inclusion in the national medical insurance directory, with specific pricing established [18] - ZhiXiang JinTai's monoclonal antibody has been included in the national medical insurance directory, which is expected to positively impact future sales [19] - Fosun Pharma announced multiple products have been newly included in the national medical insurance directory, which is anticipated to positively influence future performance [20] - Zejing Pharmaceutical's drug has been included in the national medical insurance directory, which will enhance affordability and market promotion [21] - Micron Biologics' product has been included in the national medical insurance directory, with no significant impact on current performance expected [22] Shareholder Commitments - Tianci Materials' controlling shareholder has committed not to reduce his shareholding in the company for six months, reflecting confidence in the company's future [23] Major Contracts - Guangqi Technology's subsidiary signed contracts worth 696 million yuan for the mass production of metamaterials, expected to impact the company's performance in 2026 [24]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 恒瑞医药(600276.SH)公告称，公司9款药品首次纳入国家医保目录，包括注射用瑞康曲妥珠单抗、苹果 酸法米替尼胶囊等。同时，11款药品新增适应症或续约成功，包括注射用卡瑞利珠单抗、氟唑帕利胶囊 等。这些药品2024年度合计销售额约为86.60亿元，2025年1-3季度合计销售额约为75.54亿元。国家医保 目录（2025年）将于2026年1月1日起正式实施。 ...

恒瑞医药公告称，部分产品纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2025年）》，将 于2026年1月1日起实施。其中，注射用瑞康曲妥珠单抗等10种药品首次纳入；注射用卡瑞利珠单抗等3 种药品新增适应症纳入；马来酸吡咯替尼片等5种药品续约成功；甲磺酸阿帕替尼片等2种药品新增适应 症并调整至常规目录管理。上述药品2024年度合计销售额约86.60亿元，2025年1-3季度约75.54亿元，对 公司业绩影响暂无法估计。 ...

新华社记者彭韵佳 日前，中国药品价格登记系统正式上线，国家医保局同步发布相关公告，9家国内外头部药企完成首批 药品价格登记。 这一独立于省级医药采购平台的全新价格系统，将给企业、患者等带来哪些影响？记者采访了相关专家 和业内人士。 新华社北京12月4日电 题：药品价格登记系统上线，将带来哪些影响？ 提供国家参考定价助力解决"出海"定价难题 "中国药品价格登记系统是应对医药创新发展新形势的全新探索，是企业构建全球化、多元化价格体系 的展示平台。"国家医保局副局长施子海说。 放眼全球，一些国家和地区在药品准入时，往往要求其提供原研国的价格作为国际参考定价。然而以 前，我国药品缺乏权威认证的价格信息，导致海外市场参考中国市场的价格时，难以找到可靠的定价依 据。 2025年以来，三生制药与辉瑞公司签订双抗创新药海外授权协议、恒瑞医药与葛兰素史克达成创新药海 外授权协议、信达生物与武田制药就双抗等创新药达成合作……我国创新药出海迎来爆发式增长。 在此背景下，创新药的国际化需要构建全球化的价格体系，需要权威的价格认证体系。 "我们的一款创新药想进入巴西市场，对方要求提供中国市场价格证明，但当时药品已纳入医保，医保 支付价 ...

新华社北京12月4日电 题：药品价格登记系统上线，将带来哪些影响？ 新华社记者彭韵佳 日前，中国药品价格登记系统正式上线，国家医保局同步发布相关公告，9家国内外头部药企完成首批药品价格登记。 这一独立于省级医药采购平台的全新价格系统，将给企业、患者等带来哪些影响？记者采访了相关专家和业内人士。 提供国家参考定价 助力解决"出海"定价难题 "中国药品价格登记系统是应对医药创新发展新形势的全新探索，是企业构建全球化、多元化价格体系的展示平台。"国家医保局副局长施子 海说。 放眼全球，一些国家和地区在药品准入时，往往要求其提供原研国的价格作为国际参考定价。然而以前，我国药品缺乏权威认证的价格信 息，导致海外市场参考中国市场的价格时，难以找到可靠的定价依据。 2025年以来，三生制药与辉瑞公司签订双抗创新药海外授权协议、恒瑞医药与葛兰素史克达成创新药海外授权协议、信达生物与武田制药就 双抗等创新药达成合作……我国创新药出海迎来爆发式增长。 在此背景下，创新药的国际化需要构建全球化的价格体系，需要权威的价格认证体系。 中国药品价格登记系统首页。 "我们的一款创新药想进入巴西市场，对方要求提供中国市场价格证明，但当时药品 ...

Core Viewpoint - The company has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with Apalutamide capsules, for first-line treatment of recurrent or metastatic cervical cancer patients [1] Drug Information - Drug Names: Injection Karilizumab (injection) and Apalutamide capsules (capsule) [1] - The application is based on a Phase III clinical study comparing Karilizumab combined with Apalutamide to platinum-based chemotherapy for recurrent or metastatic cervical cancer [1] - The study was led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, involving 45 domestic centers and enrolling 443 patients [1] - The study achieved its primary endpoint by July 2025, demonstrating that the experimental group significantly outperformed the control group in terms of progression-free survival (PFS) and overall survival (OS) [1] - The results confirm the efficacy and safety of Karilizumab combined with Apalutamide as a first-line treatment for recurrent or metastatic cervical cancer patients [1]

Core Viewpoint - Heng Rui Medicine (01276) has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with Apalutamide capsules, for first-line treatment of recurrent or metastatic cervical cancer patients [1] Group 1: Drug Development - The application for market approval is based on a Phase III clinical study comparing Karilizumab combined with Apalutamide against platinum-based chemotherapy for recurrent or metastatic cervical cancer [1] - The study was led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, involving 45 domestic centers and enrolling 443 patients [1] - The study achieved its primary endpoint by July 2025, demonstrating that the experimental group significantly outperformed the control group in terms of progression-free survival (PFS) and overall survival (OS) [1] Group 2: Efficacy and Safety - The results confirm the efficacy and safety of Karilizumab combined with Apalutamide as a first-line treatment for patients with recurrent or metastatic cervical cancer [1]

Core Viewpoint - Heng Rui Medicine has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with Apalutamide capsules, for first-line treatment of recurrent or metastatic cervical cancer patients [1] Group 1: Drug Development - The application for market approval is based on a Phase III clinical study comparing Karilizumab combined with Apalutamide to platinum-based chemotherapy for recurrent or metastatic cervical cancer [1] - The study was led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, involving 45 domestic centers and enrolling 443 patients [1] - The study achieved its primary endpoint by July 2025, demonstrating that the experimental group significantly outperformed the control group in terms of progression-free survival (PFS) and overall survival (OS) [1] Group 2: Efficacy and Safety - The results confirm the efficacy and safety of Karilizumab combined with Apalutamide as a first-line treatment for patients with recurrent or metastatic cervical cancer [1]